10 stories mentioning SHE:002653
Every FINWIRES story that references SHE:002653, newest first.
Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for the clinical trials of HSK46256 tablets, according to a Shenzhen bourse filing on Friday.The drug was developed as a treatment for advanced solid tumors.The Chinese drug company's shares rose 3% during the morning trade.
Chinese drug regulators approved Haisco Pharmaceutical Group's (SHE:002653) HSK51155 tablets, according to a Wednesday filing with the Shenzhen bourse.The pain reliever, a non-opioid analgesic, is seen to reduce adverse reactions and addiction risks, the company said in its filing.
Haisco Pharmaceutical (SHE:002653) subsidiary Haisco Pharmaceutical Technology (Lhasa) and Eli Lilly will sign a licensing and research collaboration agreement for five experimental drug projects, according to a Tuesday filing with the Shenzhen bourse.Eli Lilly will obtain global exclusive rights to the projects, except in China, Hong Kong, Macau, and Taiwan, which Haisco will handle.Haisco will be entitled to up to $87 million in upfront payments for five target projects from nomination to candidate compound confirmation, as well as up to $2.97 billion after achieving clinical, regulatory, and commercialization milestones.The Chinese drug company will also receive single-digit tiered royalties on future product sales, Haisco said in a separate press release.
Haisco Pharmaceutical (SHE:002653) obtained approval from China's National Medical Products Administration for the clinical trials of the HSK44459 cream, according to a Wednesday filing on the Shenzhen bourse.The cream will be tested as a treatment for psoriasis and atopic dermatitis.
Haisco Pharmaceutical (SHE:002653) posted first-quarter attributable net profit of 554.6 million yuan, up 1,090% from 46.6 million yuan the previous year.Earnings per share climbed to 0.50 yuan from 0.04 yuan, according to a weekend filing on the Shenzhen bourse.Operating revenue jumped 75% year over year to 1.56 billion yuan from 892.0 million yuan.Shares of the pharmaceutical company rose 2% in recent trade.
China's drug regulator approved Haisco Pharmaceutical's (SHE:002653) clinical trial for its HSK47388 tablets, according to a Thursday disclosure to the Shanghai bourse.The tablets are indicated for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Chinese equities closed flat, mainly in positive territory, slightly rebounding from earlier losses due to threats of the U.S. blocking the Strait of Hormuz.The Shanghai Composite Index moderately rose to close Monday's trade at 3,988.56. The Shenzhen Component Index added 0.7%, or 98.39 points, to 14,407.86.Investors are still cautious as talks between the U.S. and Iran crumbled, prompting President Donald Trump to announce an immediate naval blockade of the strait, which is a critical global oil passageway.Despite the growing Middle East tensions, the Asian Development Bank, or ADB, lifted its economic forecast for China for the year, bringing its gross domestic product 4.6% from the previous forecast of 4.3%. The ADB attributed the improved outlook on the government's support for high-tech innovation and continued exports as China leans towards non-U.S. global trade partners.In corporate news, Haisco Pharmaceutical (SHE:002653) soared after granting AbbVies exclusive rights for Nav1.8 inhibitors.Jinan Shengquan (SHA:605589) rose 2.7% amid plans to issue convertible bonds worth 2.50 billion yuan.
Haisco Pharmaceutical (SHE:002653) granted AbbVie Group Holdings exclusive rights to develop, manufacture, and commercialize Nav1.8 inhibitors globally, according to a Shenzhen bourse filing on Monday.The Chinese pharmaceutical company will receive an upfront payment of $30 million and additional milestone payments of up to $715 million.The scope of the exclusive rights will exclude the mainland, Hong Kong and Macau.The Nav1.8 inhibitors are HSK55718 and HSK51155, which are developed to block specific sodium ion channels and restrain abnormal neuronal firing in pain pathways.Haisco's shares jumped 4% during the afternoon trade.
Haisco Pharmaceutical (SHE:002653) expects its net profit attributable to shareholders in the first quarter surge between 923% and 1,095% year on year to 477 million yuan to 557 million yuan, according to a Shenzhen bourse filing on Monday.Earnings per share during the same period is expected to be between 0.43 yuan and 0.50 yuan.The attributable profit a year earlier was 46.6 million yuan, or 0.04 yuan per share.The pharmaceutical company's shares jumped less than 3% during the midday trade.
Haisco Pharmaceutical's (SHE:002653) net profit attributable to shareholders in 2025 fell 34% year on year to 259.6 million yuan, or 0.23 yuan per share, according to a Shenzhen bourse filing on Monday.The attributable profit a year earlier was 395.5 million yuan, or 0.35 yuan per share.Operating revenue rose 18% to 4.39 billion yuan from 3.72 billion yuan in the previous year.The pharmaceutical company's shares jumped less than 3% during the midday trade.